CD80 and cancer: Two antagonistic anti-CTLA-4 mAbs, ipilimumab (IgG1 isotype) and tremelimumab (IgG2 isotype), that block interactions between CTLA-4 and its coreceptors CD80 and CD86 have been clinically approved for advanced stage cancers.